Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.
Stocks · News reference
8-K filing — FIREFLY NEUROSCIENCE, INC. (AIFF)
Filed: 2026-09-14 AccNo: 0001213900-26-099733 Size: 275 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Firefly Neuroscience shares are trading higher after the company announced a partnership with NeuroSigma to expand access to the Monarch eTNS System through its Evoke clinician network.
Firefly Neuroscience Partners With NeuroSigma To Expand Clinician Awareness Of And Access To The Monarch eTNS System
Collaboration to use Firefly’s growing nationwide network of Evoke™ clinician customers. The Monarch eTNS® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder ("ADHD")
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.